PDEX
Strong BuyPremium GrowerFLAGPro-Dex, Inc. · Healthcare · United States · $200M · Avg Vol: $5M/d
Premium Grower: Strong business with the market behind it, but you are paying up for it.
Pro-Dex has strong quality at Q75 and momentum M66, but value at V44 is below the calibrated floor, so stage one fails. Insider selling of 0.31% is separately adverse.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT PRO-DEX, INC.
Read
Pro-Dex, Inc. is a specialized manufacturer of powered surgical instruments for medical device OEMs, including robotic surgical systems, and rotary handpieces for dental applications. The company's competitive edge stems from its deep expertise in high-precision, miniature powered rotary instruments, coupled with strong engineering capabilities and a track record of quality and reliability. Pro-Dex serves as a critical, niche supplier within the medical and dental industries, leveraging its specialized manufacturing and development capabilities.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.0M | 46.1M | 53.8M | 66.6M | 16.6% | 77.5M | 71.0M | 74.5M | 3.8% |
| EPS | 1.06 | 1.98 | 0.61 | 2.73 | 37.1% | 4.12 | 2.05 | 2.23 | -6.6% |
| Shares | 3.6M | 3.5M | 3.4M | 3.3M | -9.3% | 3.2M | — | — | — |
| Debt | 16.0M | 14.8M | 13.5M | 16.6M | 1.3% | 18.9M | — | — | — |
| Equity | 25.4M | 31.6M | 30.9M | 36.6M | 12.9% | — | — | — | — |
| Op CF | -0.8M | 5.5M | 6.2M | -1.7M | 14.0% | 7.2M | — | — | — |
| Inv CF | -1.2M | -0.9M | -2.2M | -0.2M | — | — | — | — | — |
| Fin CF | -0.8M | -2.5M | -4.3M | -0.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PDEX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PDEX | Pro-Dex, Inc.(you) | $200M | 95 | Strong Buy |
| UTMD | Utah Medical Products, Inc. | $232M | 94 | Strong Buy |
| EMBC | Embecta Corp. | $286M | 88 | Strong Buy |
| SMTI | Sanara MedTech Inc. | $318M | 68 | Buy |
| OSUR | OraSure Technologies, Inc. | $248M | 33 | Sell |
| ANGO | AngioDynamics, Inc. | $655M | 52 | Hold |
| DXR | Daxor Corporation | $60M | 50 | Hold |
| NVST | Envista Holdings Corporation | $4.4B | 85 | Strong Buy |
| STAA | STAAR Surgical Company | $1.1B | 57 | Hold |
| KRMD | KORU Medical Systems, Inc. | $148M | 25 | Sell |
Peer medians: ROE -31.0% · P/E 25.2x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.